相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas
Guillem Pascual-Pasto et al.
JOURNAL OF CONTROLLED RELEASE (2022)
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
Naruto Taira et al.
BREAST CANCER (2022)
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer
Hisashi Tanaka et al.
CLINICAL LUNG CANCER (2021)
Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan et al.
ONCOLOGIST (2021)
The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium
Tom Wei-Wu Chen et al.
CANCER SCIENCE (2021)
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study
Gerald W. Prager et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial
Davendra P. S. Sohal et al.
JAMA ONCOLOGY (2021)
Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis
Miao Liu et al.
BMC CANCER (2021)
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
Junji Tsurutani et al.
BREAST (2021)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial
Peter Oppelt et al.
MEDICAL ONCOLOGY (2021)
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature
Anna M. Frezza et al.
CANCER MEDICINE (2021)
Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(R) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)
Daniel Pink et al.
CANCERS (2021)
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach
Jung Won Chun et al.
BMC CANCER (2021)
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
Yasuto Yoneshima et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma
Dijian Shen et al.
JOURNAL OF THORACIC DISEASE (2021)
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial
Jie Wang et al.
JAMA ONCOLOGY (2021)
The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer
Jiangfeng Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
Jakob M. Riedl et al.
EUROPEAN JOURNAL OF CANCER (2021)
Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles
Le Minh Pham et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Muyue Yang et al.
BIOACTIVE MATERIALS (2021)
Randomized phase II trial of carboplatin plus nab-paclitaxel versus cisplatin plus gemcitabine for chemotherapy-naive squamous cell carcinoma: North Japan lung cancer study group 1302
Yosuke Kawashima et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plusnab-paclitaxel: a case report and literature review
Yoshinori Kikuchi et al.
INTERNATIONAL CANCER CONFERENCE JOURNAL (2021)
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience
A. Parisi et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Sarcoma Surveillance: A Review of Current Evidence and Guidelines
Cara A. Cipriano et al.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS (2020)
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
Yuko Tsuchiya-Kawano et al.
ONCOLOGIST (2020)
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis
Hwaryeon Lee et al.
SCIENTIFIC REPORTS (2020)
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
Francesco Gelsomino et al.
BRITISH JOURNAL OF CANCER (2020)
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients
Herbert J. Zeh et al.
CLINICAL CANCER RESEARCH (2020)
Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation
Javier E. Oesterheld et al.
PEDIATRIC BLOOD & CANCER (2020)
Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Syed A. Ahmad et al.
ANNALS OF SURGERY (2020)
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
Loredana Amoroso et al.
EUROPEAN JOURNAL OF CANCER (2020)
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
Zhichao Tian et al.
BMC CANCER (2020)
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Giampaolo Perri et al.
JAMA SURGERY (2020)
Adjuvant FOLFOX plus Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer A Brown University Oncology Research Group Phase II Study (BrUOG295)
Alexander G. Raufi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
P. Giannatempo et al.
ANNALS OF ONCOLOGY (2020)
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Margaret von Mehren et al.
Journal of the National Comprehensive Cancer Network (2020)
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
Atsuo Takashima et al.
GASTRIC CANCER (2019)
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
Takashi Higuchi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
Zhen Wang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Current advances in development of new docetaxel formulations
Enhui Zhang et al.
EXPERT OPINION ON DRUG DELIVERY (2019)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff et al.
JAMA ONCOLOGY (2019)
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer
Rikiya Hasegawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
Hajime Asahina et al.
LUNG CANCER (2019)
Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study
Marie-Rose B. S. Crombag et al.
PHARMACEUTICAL RESEARCH (2019)
A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer
Kan Wu et al.
JOURNAL OF THORACIC DISEASE (2019)
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)
S. Watson et al.
EUROPEAN JOURNAL OF CANCER (2019)
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
Teresa Macarulla et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma
Jee Hung Kim et al.
ONCOLOGY (2019)
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study
Marie-Rose B. S. Crombag et al.
PHARMACEUTICAL RESEARCH (2019)
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
Lucas Moreno et al.
EUROPEAN JOURNAL OF CANCER (2018)
Soft Tissue Sarcoma, Version 2.2018
Margaret von Mehren et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas
Jonathan L. Metts et al.
PEDIATRIC BLOOD & CANCER (2018)
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
Michele Reni et al.
EUROPEAN JOURNAL OF CANCER (2018)
Prognostic factors for survival in Ewing sarcoma: A systematic review
S. E. Bosma et al.
SURGICAL ONCOLOGY-OXFORD (2018)
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
Vaibhav Sahai et al.
JAMA ONCOLOGY (2018)
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
Ajeet Gajra et al.
FRONTIERS IN ONCOLOGY (2018)
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Jie Xu et al.
BMC CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Developments and future clinical outlook of taxane nanomedicines
Benoit Louage et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel
Jessica Ley et al.
MEDICAL ONCOLOGY (2017)
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
Eisaku Miyauchi et al.
ONCOLOGIST (2017)
Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
Kazunori Honda et al.
CASE REPORTS IN ONCOLOGY (2017)
Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel
Natalia B. Andriguetti et al.
CURRENT MEDICINAL CHEMISTRY (2017)
The battle of nano paclitaxel
Alexandros Marios Sofias et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US
Victor M. Villalobos et al.
CLINICAL SARCOMA RESEARCH (2017)
nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings
Adam Brufsky
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Taxane anticancer agents: a patent perspective
Iwao Ojima et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Osteogenic Sarcoma: A 21st Century Review
Stephen Osasan et al.
ANTICANCER RESEARCH (2016)
Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
Hai-ying Wang et al.
ONCOTARGETS AND THERAPY (2016)
Angiosarcoma of the thoracic wall responded well to nanoparticle albumin-bound paclitaxel: A case report
Naofumi Hara et al.
DRUG DISCOVERIES AND THERAPEUTICS (2016)
Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
Lynn E. Spitler et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma
E. M. Hersh et al.
ANNALS OF ONCOLOGY (2015)
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
Nianhang Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel-How Far Science Has Come
Sami I. Bashour et al.
CLINICAL CANCER RESEARCH (2015)
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer
Zhefeng Liu et al.
MEDICAL ONCOLOGY (2015)
Pharmacologic Sensitivity of Paclitaxel to Its Delivery Vehicles Drives Distinct Clinical Outcomes of Paclitaxel Formulations
Yan Li et al.
MOLECULAR PHARMACEUTICS (2015)
APhase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas
Rodrigo R. Munhoz et al.
ONCOLOGIST (2015)
A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer
Juneko E. Grilley-Olson et al.
ONCOLOGIST (2015)
Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2015)
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Madappa Kundranda et al.
Drug Design Development and Therapy (2015)
Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age
Arti Hurria et al.
ONCOLOGIST (2015)
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
George Dranitsaris et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2015)
Clinical features of taxane neuropathy
David Kudlowitz et al.
ANTI-CANCER DRUGS (2014)
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel - a review
Vincent A. de Weger et al.
ANTI-CANCER DRUGS (2014)
Nab-paclitaxel: A flattering facelift
A. Viudez et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications
David Kudlowitz et al.
EXPERT OPINION ON DRUG SAFETY (2014)
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver
MOLECULAR BIOLOGY OF THE CELL (2014)
Preclinical Evaluation of Nanoparticle Albumin-Bound Paclitaxel for Treatment of Pediatric Bone Sarcoma
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2014)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
M. A. Socinski et al.
ANNALS OF ONCOLOGY (2013)
Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Libo Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
Carlo Lazzaro et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Docetaxel Nanotechnology in Anticancer Therapy
Pengxiang Zhao et al.
CHEMMEDCHEM (2012)
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
William J. Gradishar et al.
CLINICAL BREAST CANCER (2012)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Update on taxane development: new analogs and new formulations
Jean A. Yared et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Michael G. Teneriello et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
Nicolas Penel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
George Dranitsaris et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas
Robert G. Maki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alternative drug formulations of docetaxel: a review
Frederike K. Engels et al.
ANTI-CANCER DRUGS (2007)
Gemcitabine and docetaxel in metastatic sarcoma: Past, present, and future
Robert G. Maki
ONCOLOGIST (2007)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma
KM Leu et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High affinity binding of paclitaxel to human serum albumin
K Paál et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
J Verweij et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
